Search
Linerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.
Modafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalThe exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular … Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy.
Saprisartan
go.drugbank.com/drugs/DB01347ExperimentalSaprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. … It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [A14009].
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersNetarsudil
go.drugbank.com/drugs/DB13931ApprovedInvestigationalActing as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous … humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral
Desvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigational[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … [A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[A218721] Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form. … A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.
Motixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … [L48116] When administered alongside [filgrastim], another agent used to aid in stem cell collection, motixafortide enabled the collection of an adequate number of stem cells in ~92% of patients within
Fenofibric acid
go.drugbank.com/drugs/DB13873ApprovedInvestigationalFenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. … It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.
Clofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnIt was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. … [A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis